Points of VUE

October 9, 2024

Vizgen and Ultivue Merge to Enable Deeper Insights into Disease Mechanisms and Drive Innovation in Spatial Multi-Omics

April 3, 2024

Ultivue Announces its STARVUE™ Image Data Science Platform, Providing Researchers with an Integrated, AI-Driven Analytical Solution for Generating Spatial Insights Copy

November 2, 2023

Ultivue announces launch of new configurable multiplex spatial panels at the Society for Immunotherapy of Cancer 2023 meeting

June 8, 2023

Ultivue announces latest financing, leadership update

Ultivue, Inc., an industry leader in multiplexing tools and novel image analysis solutions for tissue biomarker studies, announced its most recent equity capital raise. The round was led by ARCH Venture Partners and Northpond Ventures. Other participants in the financing include Yonghua Capital, Tao Capital Partners, Applied Ventures and Liberty Lane Partners. Proceeds from the raise will be used for continued commercial development, sustained progress in creating operational efficiencies and advancement of Ultivue’s innovation pipeline.

Announcement

November 15, 2022

EVIDENT and Ultivue Collaborate to Advance Multiplex Slide Imaging and Spatial Analysis in Translational Research

Combining Ultivue’s mIF assays with the Olympus SLIDEVIEW™ VS200 research slide scanner provides a convenient, fast tool for whole slide mIF imaging in translational studies for researchers in academia, biotech, pharma and contract research organizations in the Americas. The collaboration builds on their existing partnership to meet the scientific community’s increasing need for fluorescent multiplexing.

Announcement

November 3, 2022

Ultivue and ZEISS to Co-Market Complete Solution for Spatial Phenomics

Ultivue VUE panels for multiplex immune-labeling offer endless options for researchers to characterize complex, tissue immune biology. With unprecedented signal-to-noise and options for pre-designed panels or customized panels, Ultivue solutions are designed to label tissues for in-depth data mining for spatial phenomics. The ZEISS Axioscan automated whole slide imager offers unparalleled fluorescence imaging and resolution

Announcement

September 29, 2022

Ultivue and ngTMA® Announce Collaborative Agreement to Provide Multiplex and Spatial Analysis for Clinical Research

Ultivue develops unique solutions for use in mIF applications, imaging, and spatial phenomics. Its proprietary InSituPlex® technology enabling improved signal to noise data is designed for fast and comprehensive exploration of biologically relevant targets, up to 12-plex, with same slide-H&E analysis in tissue samples combines the power of computational pathology & spatial biology to guide

Announcement

April 7, 2022

Ultivue Announces Co-Marketing and Co-Development Collaboration with Paige for AI-Powered Biomarker Imaging Solutions for Precision Medicine

Collaborative efforts will initially focus on the development of AI to enable improved understanding of the tumor microenvironment and support the interpretation of Ultivue’s novel multiplex immunofluorescence (mIF) immuno-oncology biomarker panels. The Paige portfolio includes the Paige Platform, a comprehensive imaging solution composed of the FDA-cleared and CE-marked FullFocus™, an intuitive and responsive viewer for

Announcement

April 6, 2022

Ultivue Announces Multiple Events for Multiplex Immunofluorescence and Image Analysis Technology in Immuno-Oncology Research at AACR 2022

Accepted abstracts during the AACR conference will feature new data from a streamlined pre-optimized protocol enabling mIF staining on mouse tissue for an improved workflow to investigate T-cell infiltration and additional analysis of the tumor immune microenvironment (TiME) to address the mechanisms of action of immune-related drugs in preclinical syngeneic or GEMM mouse models. The

Announcement

March 29, 2022

Keen Eye and Ultivue announce collaborative agreement to propel multiplex and spatial analysis in clinical research

Keen Eye, a leading AI company in digital pathology for clinical research and Ultivue, Inc. an industry leader in multiplexing tools and novel image analysis solutions for tissue biomarker studies, announce a collaborative agreement to promote multiplexed immunofluorescence (mIF) assays and novel AI applications to unlock spatial analysis in clinical research.

Announcement

March 9, 2022

Unique Spatial AI-Powered Imaging Solutions for Translational Medicine

Ultivue, Inc. and Aignostics GmbH announced a partnership to collaborate on the co-development of AI-powered spatial multiplexed immunophenotype solutions for translational research groups and Biopharma.

Announcement

February 9, 2022

Ultivue Announces Relocation and Expansion for New Corporate Headquarters

Ultivue, Inc. announced the relocation and expansion of its corporate headquarters to a new office and laboratory facility in Burlington, MA to advance the operations and growth of the company. Avison Young’s Boston office arranged a new 56,000-square-foot lease on behalf of biotechnology company Ultivue at Burlington Biocenter. Ultivue will relocate and triple in size from its previous Cambridge location in the Fall of 2022.

Announcement

November 4, 2021

Ultivue to Participate in the Stifel 2021 Virtual Healthcare Conference

Ultivue, an industry leader in multiplexing tools for tissue biomarker analysis, will participate in the Stifel 2021 Virtual Healthcare Conference to be held November 15th – 17, 2021. The conference incorporates presentations and innovative panel discussions hosted by senior leadership in the health care industry.

Announcement